Comparison of the effectiveness and speed of shivering treatment after general anesthesia with pethidine and doxapram in patients undergoing orthopedic surgery and urological surgery referred to Firoozgar Hospital in Tehran.

开始日期2020-08-22

申办/合作机构

Iran University of Medical Sciences & Health Services

100 项与盐酸多沙普仑相关的临床结果

登录后查看更多信息

100 项与盐酸多沙普仑相关的转化医学

登录后查看更多信息

100 项与盐酸多沙普仑相关的专利（医药）

登录后查看更多信息

557

项与盐酸多沙普仑相关的文献（医药）

2024-05-27·Journal of comparative physiology. A, Neuroethology, sensory, neural, and behavioral physiology

The effects of doxapram and its potential interactions with K2P channels in experimental model preparations.

Article

作者: Brock, Kaitlyn E ; Vacassenno, Rachael M ; Harrison, Douglas A ; Elliott, Elizabeth R ; Cooper, Robin L

The channels commonly responsible for maintaining cell resting membrane potentials are referred to as K2P (two-P-domain K⁺ subunit) channels. These K⁺ ion channels generally remain open but can be modulated by their local environment. These channels are classified based on pharmacology, pH sensitivity, mechanical stretch, and ionic permeability. Little is known about the physiological nature of these K2P channels in invertebrates. Acidic conditions depolarize neurons and muscle fibers, which may be caused by K2P channels given that one subtype can be blocked by acidic conditions. Doxapram is used clinically as a respiratory aid known to block acid-sensitive K2P channels; thus, the effects of doxapram on the muscle fibers and synaptic transmission in larval Drosophila and crawfish were monitored. A dose-dependent response was observed via depolarization of the larval Drosophila muscle and an increase in evoked synaptic transmission, but doxapram blocked the production of action potentials in the crawfish motor neuron and had a minor effect on the resting membrane potential of the crawfish muscle. This indicates that the nerve and muscle tissues in larval Drosophila and crawfish likely express different K2P channel subtypes. Since these organisms serve as physiological models for neurobiology and physiology, it would be of interest to further investigate what types of K2P channel are expressed in these tissues. (212 words).

2023-11-01·Journal of Veterinary Pharmacology and Therapeutics

The effect of doxapram on survival and APGAR score in newborn puppies delivered by elective caesarean: A randomized controlled trial

Article

作者: Kordzakhia, Nino ; Hyndman, Timothy H ; Bowden, Ross S ; Irons, Peter C ; Coaicetto, Flaminia ; Mosing, Martina ; Page, Stephen W ; Fretwell, Shelby ; Musk, Gabrielle C ; Tuke, S Jonathan ; Metcalfe, Steven S ; Aleri, Joshua W

AbstractDoxapram is marketed as a respiratory stimulant and is used by some veterinarians to help with neonatal apnoea, especially in puppies delivered by caesarean. There is a lack of consensus as to whether the drug is effective and data on its safety are limited. Doxapram was compared to placebo (saline) in newborn puppies in a randomized, double‐blinded clinical trial using two outcome measures: 7‐day mortality rate and repeated APGAR score measurements. Higher APGAR scores have been positively correlated with survival and other health outcomes in newborns. Puppies were delivered by caesarean and a baseline APGAR score was measured. This was immediately followed by a randomly allocated intralingual injection of either doxapram or isotonic saline (of the same volume). Injection volumes were determined by the weight of the puppy and each injection was administered within a minute of birth. The mean dose of doxapram administered was 10.65 mg/kg. APGAR scores were measured again at 2, 5, 10 and 20 min. One hundred and seventy‐one puppies from 45 elective caesareans were recruited into this study. Five out of 85 puppies died after receiving saline and 7 out of 86 died after receiving doxapram. Adjusting for the baseline APGAR score, the age of the mother and whether the puppy was a brachycephalic breed, there was insufficient evidence to conclude a difference in the odds of 7‐day survival for puppies that received doxapram compared to those that received saline (p = .634). Adjusting for the baseline APGAR score, the weight of the mother, the litter size, the mother's parity number, the weight of the puppy and whether the puppy was a brachycephalic breed, there was insufficient evidence to conclude a difference in the probability of a puppy having an APGAR score of ten (the maximum APGAR score) between those that received doxapram compared to those that received saline (p = .631). Being a brachycephalic breed was not associated with an increased odds of 7‐day mortality (p = .156) but the effect of the baseline APGAR score on the probability of having an APGAR score of ten was higher for brachycephalic than non‐brachycephalic breeds (p = .01). There was insufficient evidence that intralingual doxapram provided an advantage (or disadvantage) compared to intralingual saline when used routinely in puppies delivered by elective caesarean and that were not apnoeic.

2023-10-01·Minerva anestesiologica

Pharmacologic interventions for the therapy of postanesthetic shivering in adults: a systematic review and network meta-analysis.

Review

作者: Wulf, Hinnerk ; Schubert, Ann-Kristin ; Al-Dahna, Turfa ; Wiesmann, Thomas ; Eberhart, Leopold ; Dinges, Hanns-Christian ; Rücker, Gerta

INTRODUCTIONShivering is a common side effect after general anesthesia. Risk factors are hypothermia, young age and postoperative pain. Severe complications of shivering are rare but can occur due to increased oxygen consumption. Previous systematic reviews are outdated and have summarized the evidence on the topic using only pairwise comparisons. The objective of this manuscript was a quantitative synthesis of evidence on pharmacological interventions to treat postanesthetic shivering.EVIDENCE ACQUSITIONSystematic review and frequentist network meta-analysis using the R package netmeta. Endpoints were the risk ratio (RR) of persistent shivering at one, five and 10 minutes after treatment with saline/placebo as the comparator. Data were retrieved from Medline, Embase, Central and Web of Science up to January 2022. Eligibility criteria were: randomized, controlled, and blinded trials comparing pharmacological interventions to treat shivering after general anesthesia. Studies on shivering during or after any type of regional anesthesia were excluded as well as sedated patients after cardiac surgery.EVIDENCE SYNTHESISThirty-two trials were eligible for data synthesis, including 28 pharmacological interventions. The largest network included 1431 patients. The network geometry was two-centered with most comparisons linked to saline/placebo or pethidine. The best interventions were after one minute: doxapram 2 mg/kg, tramadol 2 mg/kg and nefopam 10 mg, after 5 minutes: tramadol 2 mg/kg, nefopam 10 mg and clonidine 150 µg and after 10 minutes: nefopam 10 mg, methylphenidate 20 mg and tramadol 1 mg/kg, all reaching statistical significance. Pethidine 25 mg and clonidine 75 µg also performed well and with statistical significance in all networks.CONCLUSIONSNefopam, tramadol, pethidine and clonidine are the most effective treatments to stop postanesthetic shivering. The efficacy of doxapram is uncertain since different doses showed contradictory effects and the evidence for methylphenidate is based on a single comparison in only one network. Furthermore, both lack data on side effects. Further studies are needed to clarify the efficacy of dexmedetomidine to treat postanesthetic shivering.

项与盐酸多沙普仑相关的新闻（医药）

2023-03-14

·蒲公英Ouryao

参比制剂目录（第65批）正式发布！

‍‍‍‍转自：国家药监局编辑：wangxinglai20042023年03月14日，国家药监局发布了第65批次仿制药一致性评价参比制剂目录，其中新增品种67个、变更及增加持证商品种21个。通知原文经国家药品监督管理局仿制药质量和疗效一致性评价专家委员会审核确定，现发布仿制药参比制剂目录（第六十五批）。涉及品种：非那雄胺片、阿伐替尼片、布美他尼片、尼索地平缓释片、盐酸地尔硫卓缓释胶囊、吲哚美辛搽剂、雌二醇醋酸炔诺酮片、利伐沙班口崩片、低钙腹膜透析液（乳酸盐-G1.5%）、低钙腹膜透析液（乳酸盐-G2.5%）、注射用头孢唑肟钠、普伐他汀钠片、马来酸噻吗洛尔滴眼液、孟鲁司特钠咀嚼片、氯沙坦钾氢氯噻嗪片、卡波姆滴眼液、氯化镭[223Ra]注射液、注射用硫酸艾沙康唑、琥珀酰明胶电解质醋酸钠注射液、普拉左米星注射液、注射用盐酸曲拉西利、克拉考特酮乳膏、富马酸伊布利特注射液、木聚硫钠胶囊、米拉贝隆缓释干混悬剂、硫酸艾沙康唑胶囊、醋酸地非法林注射液、盐酸赛洛唑啉鼻用喷雾剂、盐酸多沙普仑注射液、聚乙烯醇滴眼液、丙酸交沙霉素糖浆剂、甲苯磺酸妥舒沙星片、布地奈德缓释胶囊、曲安奈德鼻喷雾剂、盐酸他喷他多片、氯化钾缓释胶囊、恩格列净利格列汀片、硫酸镁钠钾口服用浓溶液、盐酸奥昔布宁缓释片、二甲双胍恩格列净片等；仿制药参比制剂目录（第65批）（扫描二维码下载附件）仿制药参比制剂目录（第65批）‍‍

一致性评价

2023-01-07

·蒲公英Ouryao

89个品种新增挂网、公示期截止1月10日！

转自：江苏省公共资源中心编辑：wangxinglai20042023年01月06日，江苏省公共资源中心发布了《关于公示药品阳光采购拟挂网产品的通知》，本次涉及89个产品，公示期为2023年1月6日至1月10日。通知原文各相关药品生产企业：根据《江苏省医疗保障局关于深入推进药品阳光采购的实施意见》（苏医保发〔2021〕64号）、《关于公示药品阳光挂网产品的函》（苏价采中心药函〔2023〕2号、苏价采中心药函〔2023〕3号）的要求，已按相关程序进行了审核与确认，现将药品阳光采购拟挂网产品予以公示，共89个品种，具体包括：注射用异环磷酰胺、注射用盐酸多沙普仑、妥布霉素吸入溶液、注射用右雷佐生、注射用头孢米诺钠、阿立哌唑口崩片、曲安奈德口腔软膏、钆喷酸葡胺注射液、复方布洛芬片、降脂灵颗粒、小儿化痰止咳颗粒等；公示期为2023年1月6日至1月10日17：00。如有异议，企业须在公示期内通过江苏省公共资源交易平台（药品分类采购-其他-阳光挂网采购申诉（202301-1））进行申诉，并提交相关证明材料。

带量采购

2022-09-05

·蒲公英Ouryao

药典委：盐酸环丙沙星等6个化药标准草案公示

转自：药典委编辑：水晶9月5日，药典委公示了盐酸氮芥、盐酸多沙普仑、盐酸赛洛唑啉、托吡卡胺、盐酸环丙沙星、盐酸特比萘芬共6个国家药品标准草案，公示期自发布之日起一个月。1、盐酸氮芥我委拟修订盐酸多沙普仑国家药品标准，标准编号：《中国药典》2020年版二部。为确保标准的科学性、合理性和适用性，现将拟修订的盐酸多沙普仑国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起一个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。公示期满未回复意见即视为对公示标准草案无异议。联系人：岳志华；郭伟电话：010-67079576；010-67079558 电子邮箱：yuezhihua@chp.org.cn 通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 国家药典委员会 2022年09月05日扫描二维码下载附件：2、盐酸多沙普仑我委拟修订盐酸多沙普仑国家药品标准，标准编号：《中国药典》2020年版二部。为确保标准的科学性、合理性和适用性，现将拟修订的盐酸多沙普仑国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起一个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。公示期满未回复意见即视为对公示标准草案无异议。联系人：岳志华；郭伟电话：010-67079576；010-67079558 电子邮箱：yuezhihua@chp.org.cn 通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 国家药典委员会 2022年09月05日扫描二维码下载附件：3、盐酸赛洛唑啉我委拟修订盐酸赛洛唑啉国家药品标准，标准编号：《中国药典》2020年版二部。为确保标准的科学性、合理性和适用性，现将拟修订的盐酸赛洛唑啉国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起一个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。公示期满未回复意见即视为对公示标准草案无异议。联系人：岳志华；郭伟电话：010-67079576；010-67079558 电子邮箱：yuezhihua@chp.org.cn 通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 国家药典委员会 2022年09月05日扫描二维码下载附件：4、托吡卡胺我委拟修订托吡卡胺国家药品标准，标准编号：《中国药典》2020年版二部。为确保标准的科学性、合理性和适用性，现将拟修订的托吡卡胺药典标准公示征求社会各界意见（详见附件）。公示期自发布之日起一个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。公示期满未回复意见即视为对公示标准草案无异议。联系人：岳志华；郭伟电话：010-67079576；010-67079558 电子邮箱：yuezhihua@chp.org.cn 通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 国家药典委员会 2022年09月05日扫描二维码下载附件：5、盐酸环丙沙星我委拟修订盐酸环丙沙星国家药品标准，标准编号：《中国药典》2020年版二部。为确保标准的科学性、合理性和适用性，现将拟修订的盐酸环丙沙星国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起一个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：王志军；郭伟电话：010-67079559；010-67079558 电子邮箱：wangzhijun@chp.org.cn 通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 国家药典委员会 2022年09月05日扫描二维码下载附件：6、盐酸特比萘芬我委拟修订盐酸特比萘芬国家药品标准，标准编号：《中国药典》2020年版二部。为确保标准的科学性、合理性和适用性，现将拟修订的盐酸特比萘芬国家药品标准公示征求社会各界意见（详见附件）。公示期自发布之日起一个月。请认真研核，若有异议，请及时来函提交反馈意见，并附相关说明、实验数据和联系方式。相关单位来函需加盖公章，个人来函需本人签名，同时将电子版发送至指定邮箱。联系人：王志军；郭伟电话：010-67079559；010-67079558 电子邮箱：wangzhijun@chp.org.cn 通信地址：北京市东城区法华南里11号楼国家药典委员会办公室邮编：100061 国家药典委员会 2022年09月05日扫描二维码下载附件：推荐阅读：蒲公英Ouryao视频号我们上线了蒲公英Ouryao视频号，每期3分钟，学习制药英语，用制药点燃你的语言星球。你的每一次“在看”，我都看得见！

100 项与盐酸多沙普仑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01872	盐酸多沙普仑	R07AB01	DB00561

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
呼吸功能不全	中国	西安力邦制药有限公司	1991-01-01
呼吸功能不全	中国	陕西得安制药有限责任公司	1991-01-01
呼吸暂停	日本	Kissei Pharmaceutical Co., Ltd.	1976-02-14
肺部疾病	美国	Hikma Pharmaceuticals USA, Inc.	1965-06-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2022	N/A	-	-	Doxapram	餘膚積遞鏇繭壓範製獵(築廠構繭鏇製繭鹽壓糧) = 鹽夢膚繭壓鑰廠鑰齋鏇夢廠醖顧衊選壓艱廠鹹 (鹹遞夢襯選獵選衊廠鹽 ) 更多	-	2022-08-27
				Ketodoxapram	餘膚積遞鏇繭壓範製獵(築廠構繭鏇製繭鹽壓糧) = 醖構壓淵鹽鏇積築醖襯夢廠醖顧衊選壓艱廠鹹 (鹹遞夢襯選獵選衊廠鹽 ) 更多
ESC2019	N/A	心房颤动	-	Doxapram	繭鏇鹹襯顧衊簾築觸夢(艱簾顧廠範積夢鑰觸壓) = 艱齋蓋構繭蓋網遞餘膚醖蓋餘顧製鑰網壓艱艱 (鏇廠夢壓繭顧觸範窪簾 )	-	2019-09-01
NCT00477451 (CTgov)	临床2期	恐慌 \| 惊恐障碍	49	Inhaled placebo+IV doxapram (RCT Placebo)	繭製選鑰顧壓網衊醖製(網鹽鹹鏇醖製網築繭窪) = 繭蓋觸齋鑰鬱衊範餘壓醖顧顧鏇願製餘膚鬱齋 (鏇鹽膚艱鏇齋築築鏇遞, 壓鏇獵鏇壓範鬱範艱選 ~ 簾簾鬱願築製獵獵築蓋) 更多	-	2017-06-16
				IV doxapram+Inhaled alprazolam 1 mg (RCT Alprazolam 1 mg)	繭製選鑰顧壓網衊醖製(網鹽鹹鏇醖製網築繭窪) = 鏇積築選淵膚窪膚窪廠醖顧顧鏇願製餘膚鬱齋 (鏇鹽膚艱鏇齋築築鏇遞, 鬱鑰鑰窪簾醖憲膚鬱廠 ~ 顧糧夢築網夢願齋網構) 更多
NCT00389909 (Pubmed \| Paediatr Drugs)	临床4期	呼吸暂停三线	85	Doxapram dosing adjusted for gender and postmenstrual age (GrA)	(淵簾鏇鹹觸壓鹽蓋鏇艱) = 齋憲鹹淵鬱膚齋廠範憲獵窪壓鏇範網壓壓壓願 (鏇壓窪糧鏇簾餘襯觸壓 )	-	2016-12-01
				Doxapram (Infants' weight alone (GrW))	(淵簾鏇鹹觸壓鹽蓋鏇艱) = 顧鹹願齋壓糧鬱醖鬱淵獵窪壓鏇範網壓壓壓願 (鏇壓窪糧鏇簾餘襯觸壓 )